A phase 2 trial in early-stage classical Hodgkin lymphoma reported high response and durable disease control with a regimen pairing two targeted drugs alongside a de-escalated chemotherapy backbone. In results published in the study coverage, complete responses were reported in 92% of patients, with an estimated 97% of participants maintaining disease control at two years. The study suggests an approach to reduce chemotherapy intensity while keeping efficacy, a strategy aligned with broader oncology movement toward precision de-escalation for patients at lower risk of relapse. On the clinical side, the next critical steps will be whether long-term follow-up sustains outcomes and whether biomarker-driven stratification can identify which patients can safely avoid intensification.